Arctic TherapeuticsFinancingArctic Therapeutics ASA kicks off with €...Iceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases … more ➔
EU ParliamentBiologisation of industryEuropaBio calling for EU Biotech ActEuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy. more ➔
adobe stock.com - HomuGallery EMAPRAC: Semaglutide linked to rare eye disea...The Safety Committee PRAC of the European Medicines Agency EMA is investigating a new potential adverse reaction to the appetite suppressant semaglutide. Epidemiological studies indicate that the rare … more ➔
InflaRx Acute Respiratory Distress SyndromeInflaRx secures European Commission approv...Jena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced … more ➔
David_SMC from PixabayInfectious diseaseSynairgen raises £18m for Phase 2 INVENT...Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, … more ➔
By Vaccinationist - PubChem, WikipediaIntra-CellularJohnson & Johnson acquires Intra-Cell...Johnson & Johnson has announced the acquisition of biopharmaceutical company Intra-Cellular Therapies, strengthening its position in the market for central nervous system disorder treatments. The $14.6 … more ➔
robin_24, WikipediaLeyden LabsLeyden Labs secures $70M to advance intran...Leyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza … more ➔
Clinical trialsFirst in vivo CAR gene therapy trial in Eu...The Paul Ehrlich Institute (PEI) has approved expansion of the global INVISE Phase 1 clinical trial to Europe. The study aims to evaluate first-in-class gene therapy for the treatment of B-cell mali … more ➔
Image by Pete Linforth from Pixabay.Angelini VenturesAngelini Ventures co-leads €20m Series A...Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna … more ➔
Justlight, AdobeStockArgobioNew RNA company Inverna Therapeutics launc...Inverna Therapeutics, a Danish biotech company, has officially launched to develop innovative RNA-based therapies targeting severe genetic diseases. Co-founded by the University of Southern Denmark and … more ➔